scholarly journals Intravenous Compared to Oral Busulfan with Cyclophosphamide for Autologous Hematopoietic Progenitor Cell Transplant Conditioning for Plasma Cell Myeloma

2013 ◽  
Vol 19 (2) ◽  
pp. S190
Author(s):  
Ronald Sobecks ◽  
Lisa Rybicki ◽  
Robert M. Dean ◽  
Donna Abounader ◽  
S. Andresen ◽  
...  
Keyword(s):  
Plasma Cell ◽  
Progenitor Cell ◽  
Hematopoietic Progenitor Cell ◽  
Cell Transplant ◽  
Plasma Cell Myeloma ◽  
Hematopoietic Progenitor

scholarly journals Mobilization of hematopoietic progenitor cells for autologous transportation: consensus recommendations

2016 ◽  
Vol 62 (suppl 1) ◽  
pp. 10-15 ◽  
Author(s):  
Fernando Barroso Duarte ◽  
Benedito de Pina Almeida Prado ◽  
Garles Miller Matias Vieira ◽  
Luciano J. Costa
Keyword(s):  
Bone Marrow ◽  
Progenitor Cells ◽  
Blood Circulation ◽  
Progenitor Cell ◽  
National Health System ◽  
Hematopoietic Progenitor Cell ◽  
Cell Transplant ◽  
Hematopoietic Progenitor ◽  
Term Survival

SUMMARY Selected patients with certain hematological malignancies and solid tumors have the potential to achieve long-term survival with autologous hematopoietic progenitor cell transplant. The collection of these cells in peripheral blood avoids multiple bone marrow aspirations, results in faster engraftment and allows treatment of patients with infection, fibrosis, or bone marrow hypocellularity. However, for the procedure to be successful, it is essential to mobilize a sufficient number of progenitor cells from the bone marrow into the blood circulation. Therefore, a group of Brazilian experts met in order to develop recommendations for mobilization strategies adapted to the reality of the Brazilian national health system, which could help minimize the risk of failure, reduce toxicity and improve the allocation of financial resources.

Sign in / Sign up

Export Citation Format

Share Document